Rytelo is approved for low-risk MDS patients with transfusion-dependent anemia, excluding those with isolated deletion 5q. Phase 3 IMerge trial data demonstrated significant reduction in red blood ...

The nature of immune dysregulation is markedly different between various MDS risk groups. In low-risk MDS, the immune system is in a proinflammatory state, whereas in high-risk disease ...

real-world registry enrolling adult patients diagnosed with lower-risk MDS—defined as International Prognostic Scoring System low or intermediate-1—in 16 European countries and Israel.

for diagnosing myelodysplastic syndrome (MDS), including in low-risk patients. A new validation study affirms the value of flow cytometry to diagnose myelodysplastic neoplasms in cytopenic patients.

low or intermediate risk myelodysplastic syndromes (lower-risk MDS or LR-MDS) without an isolated deletion 5q cytogenetic (non-del 5q) abnormality and who had an unsatisfactory response to or are ...

The biotech has launched a strategic review to consider options, including a possible sale, following shareholder pressure.

If approved, it would compete with Bristol-Myers Squibb’s erythroid maturation agent Reblozyl (luspatercept), which was cleared to treat anaemia in adults with low-risk, relapsed MDS in 2020 and ...

During a live event, Chris Benton, MD, discussed the focus on anemia management, reducing transfusions, and improving quality ...

Bexmarilimab and Vidaza achieved high response rates in higher-risk myelodysplastic syndrome, meeting the phase 2 BEXMAB trial's primary endpoint. The treatment demonstrated a 63% objective response ...